Coated medical devices for the prevention and treatment of...

Details Coated medical devices for the prevention and treatment of... Coated medical devices for the prevention and treatment of...

2008-09-02

2008-09-02

Kennedy, Sharon (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C623S001420

Reexamination Certificate

active

10431059

ABSTRACT:
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 5500013 (1996-03-01), Buscemi et al.
patent: 6071305 (2000-06-01), Brown et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6245537 (2001-06-01), Williams et al.
patent: 6273913 (2001-08-01), Wright et al.
patent: 6335029 (2002-01-01), Kamath et al.
patent: 6379379 (2002-04-01), Wang
patent: 6743463 (2004-06-01), Weber et al.
patent: 6752829 (2004-06-01), Kocur et al.
patent: 6759054 (2004-07-01), Chen et al.
patent: 6776796 (2004-08-01), Falotico et al.
patent: 6790228 (2004-09-01), Hossainy et al.
patent: 6818247 (2004-11-01), Chen et al.
patent: 6899731 (2005-05-01), Li et al.
patent: 6939376 (2005-09-01), Shulze et al.
patent: 7056338 (2006-06-01), Shanley et al.
patent: 7169178 (2007-01-01), Santos et al.
patent: 7238199 (2007-07-01), Feldman et al.
patent: 7261735 (2007-08-01), Llanos et al.
patent: 2001/0029351 (2001-10-01), Falotico et al.
patent: 2005/0136090 (2005-06-01), Falotico et al.
patent: 2005/0158360 (2005-07-01), Falotico et al.
patent: 2005/0202059 (2005-09-01), Falotico et al.
patent: 2005/0208092 (2005-09-01), Falotico et al.
patent: 2005/0209688 (2005-09-01), Falotico et al.
patent: 2006/0198867 (2006-09-01), Toner et al.
patent: WO 01/87372 (2001-11-01), None
patent: WO 01/87373 (2001-11-01), None
patent: WO 01/87375 (2001-11-01), None
patent: WO 02/26271 (2002-04-01), None
patent: WO 02/26139 (2003-04-01), None
patent: 02/26139 (2004-04-01), None
patent: 01/87375 (2004-11-01), None
Copending U.S. Appl. No. 09/575,480.
U.S. Appl. No. 60/381,986, filed May 20, 2002, Falotico.
U.S. Appl. No. 60/204,417, filed May 12, 2000, Kopia.
U.S. Appl. No. 09/575,480, filed May 19, 2000, Kopia.
U.S. Appl. No. 09/850,293, filed May 7, 2001, Falotico.
Berk, B.C.-et al., “Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty”, J. Am. Coll. Cardio. vol. 17, No. 6, pp. 111B-117B, 1991.
Chang, M.W. et al., “Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty”, J. Clin. Invest. vol. 96, pp. 2260-2268, 1995.
Clowes, A.W. et al., “Suppression by heparin of smooth muscle cell proliferation in injured arteries”, Nature, vol. 265, pp. 625-626, 1977.
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury”, Laboratory Investigation, vol. 52, No. 6, pp. 611-616, 1985.
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury IV. Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration”, Circulation Research, vol. 58, No. 6, pp. 839-845, 1986.
Colburn, M.D. et al., “Dose responsive suppression of myointimal hyperplasia by dexamethasone”, J. Vasc. Surg. vol. 15, No. 3, pp. 510-518, 1992.
Currier, J.W. et al., “Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit”, Supplement II Circulation vol. 80, No. 4, II-66, 1989.
Farb, A. et al., “Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein”, Circ. Res. vol. 80, No. 4, pp. 542-550, 1997.
Ferns, G.A. et al., “Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF”, Science, vol. 253, pp. 1129-1132, 1991.
Fukuyama J., et al., “Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet”, European Journal of Pharmacology 318, pp. 327-332, 1996.
Guyton, J.R. et al., “Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin”, Circulation Research, vol. 46, No. 5, pp. 625-634, 1980.
Hansson, G.K., et al., “Interferon-γ Inhibits Arterial Stenosis After Injury” Circulation, vol. 84, No. 3, pp. 1266-1272, 1991.
Jonasson, L. et al., “Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury”, Proc. Natl. Acad. Sci. USA vol. 85, pp. 2303-2306, 1988.
Liu, M.W. et al.; “Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit”, Circ. vol. 81, No. 3, pp. 1089-1093, 1990.
Lundergan, C.F. et al., “Peptide Inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue”, JACC vol. 17(Supp. B), No. 6. pp. 132B-136B, 1991.
Majesky, M.W. et al.; “Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery”, Circ. Res. vol. 61, No. 2, pp. 296-300, 1987.
Marx, S.O., et al., “Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells”, Circ. Res., vol. 76, No. 3, pp. 412-417, 1995.
Nemecek, G.M. et al., “Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo”, J. Pharmacol. Exp. Thera. vol. 248, No. 3, pp. 1167-1174, 1989.
Okada, T. et al., Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation, Neurosurgery, vol. 25, No. 6, pp. 892-898, 1989.
Powell, J.S. et al., Inbitors of Antiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury, Science, vol. 245, pp. 186-188, 1989.
Rensing B.J. et al., “Coronary restenosis elimination with a sirolimus eluting stent” European Heart Journal, vol. 22, 2001, pp. 2125-2130. XP009013745.
Rodeck, C. et al., “Methods for the Transcervical Collection of Fetal Cells During the First Trimester of Pregnancy”, Prenatal Diagnosis, vol. 15, pp. 933-942, 1995.
Simons, M. et al., “Antisense c-myboligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo”, Nature, vol. 359, pp. 67-70, 1992.
Snow, A.D. et al., “Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells”, vol. 137, No. 2, pp. 313-330, 1990.
Sollott, S.J. et al., “Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation ater Angioplasty in the Rat”, J. Clinical Investigation, Inc. vol. 95, pp. 1869-1876, 1995.
Weinberger, J. et al., “Intracoronary Irradiation: Dose Response for the Prevention of Restenosis in Swine”, Int. J. Radiation Onc. Biol. Phys. vol. 36, No. 4, pp. 767-775, 1996.

Affiliated with

Also associated with

Rating

Coated medical devices for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Coated medical devices for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coated medical devices for the prevention and treatment of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3927915